Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Michael Untch; Peter A Fasching; Gottfried E Konecny; Stephan Hasmüller; Annette Lebeau; Rolf Kreienberg; Oumar Camara; Volkmar Müller; Du Bois Andreas; Thorsten Kühn; Elmar Stickeler; Nadia Harbeck; Cornelia Höss; Steffen Kahlert; Thomas Beck; Werner Fett; Keyur M Mehta; Gunter von Minckwitz; Sibylle Loibl

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Standard

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. / Untch, Michael; Fasching, Peter A; Konecny, Gottfried E; Hasmüller, Stephan; Lebeau, Annette; Kreienberg, Rolf; Camara, Oumar; Müller, Volkmar; Andreas, Du Bois; Kühn, Thorsten; Stickeler, Elmar; Harbeck, Nadia; Höss, Cornelia; Kahlert, Steffen; Beck, Thomas; Fett, Werner; Mehta, Keyur M; von Minckwitz, Gunter; Loibl, Sibylle.

In: J CLIN ONCOL, Vol. 29, No. 25, 25, 2011, p. 3351-3357.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Untch, M, Fasching, PA, Konecny, GE, Hasmüller, S, Lebeau, A, Kreienberg, R, Camara, O, Müller, V, Andreas, DB, Kühn, T, Stickeler, E, Harbeck, N, Höss, C, Kahlert, S, Beck, T, Fett, W, Mehta, KM, von Minckwitz, G & Loibl, S 2011, 'Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.', J CLIN ONCOL, vol. 29, no. 25, 25, pp. 3351-3357. <http://www.ncbi.nlm.nih.gov/pubmed/21788566?dopt=Citation>

APA

Untch, M., Fasching, P. A., Konecny, G. E., Hasmüller, S., Lebeau, A., Kreienberg, R., Camara, O., Müller, V., Andreas, D. B., Kühn, T., Stickeler, E., Harbeck, N., Höss, C., Kahlert, S., Beck, T., Fett, W., Mehta, K. M., von Minckwitz, G., & Loibl, S. (2011). Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J CLIN ONCOL, 29(25), 3351-3357. [25]. http://www.ncbi.nlm.nih.gov/pubmed/21788566?dopt=Citation

Vancouver

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J CLIN ONCOL. 2011;29(25):3351-3357. 25.

Bibtex

@article{3e87a969eca64d68b1e59ee6fd9ea978,

title = "Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.",

abstract = "To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.",

keywords = "Adult, Humans, Aged, Female, Middle Aged, Young Adult, Prospective Studies, Treatment Outcome, Cohort Studies, Survival Rate, Follow-Up Studies, Chemotherapy, Adjuvant, Remission Induction, Neoplasm Invasiveness, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Cyclophosphamide/administration & dosage, Antibodies, Monoclonal/administration & dosage, Breast Neoplasms/*drug therapy/*mortality/pathology, Carcinoma, Ductal, Breast/drug therapy/mortality/pathology, Carcinoma, Lobular/drug therapy/mortality/pathology, Epirubicin/administration & dosage, *Neoadjuvant Therapy, Paclitaxel/administration & dosage, Receptor, erbB-2/*metabolism, Adult, Humans, Aged, Female, Middle Aged, Young Adult, Prospective Studies, Treatment Outcome, Cohort Studies, Survival Rate, Follow-Up Studies, Chemotherapy, Adjuvant, Remission Induction, Neoplasm Invasiveness, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Cyclophosphamide/administration & dosage, Antibodies, Monoclonal/administration & dosage, Breast Neoplasms/*drug therapy/*mortality/pathology, Carcinoma, Ductal, Breast/drug therapy/mortality/pathology, Carcinoma, Lobular/drug therapy/mortality/pathology, Epirubicin/administration & dosage, *Neoadjuvant Therapy, Paclitaxel/administration & dosage, Receptor, erbB-2/*metabolism",

author = "Michael Untch and Fasching, {Peter A} and Konecny, {Gottfried E} and Stephan Hasm{\"u}ller and Annette Lebeau and Rolf Kreienberg and Oumar Camara and Volkmar M{\"u}ller and Andreas, {Du Bois} and Thorsten K{\"u}hn and Elmar Stickeler and Nadia Harbeck and Cornelia H{\"o}ss and Steffen Kahlert and Thomas Beck and Werner Fett and Mehta, {Keyur M} and {von Minckwitz}, Gunter and Sibylle Loibl",

year = "2011",

language = "English",

volume = "29",

pages = "3351--3357",

journal = "J CLIN ONCOL",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "25",

}

RIS

TY - JOUR

T1 - Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

AU - Untch, Michael

AU - Fasching, Peter A

AU - Konecny, Gottfried E

AU - Hasmüller, Stephan

AU - Lebeau, Annette

AU - Kreienberg, Rolf

AU - Camara, Oumar

AU - Müller, Volkmar

AU - Andreas, Du Bois

AU - Kühn, Thorsten

AU - Stickeler, Elmar

AU - Harbeck, Nadia

AU - Höss, Cornelia

AU - Kahlert, Steffen

AU - Beck, Thomas

AU - Fett, Werner

AU - Mehta, Keyur M

AU - von Minckwitz, Gunter

AU - Loibl, Sibylle

PY - 2011

Y1 - 2011

N2 - To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.

AB - To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Young Adult

KW - Prospective Studies

KW - Treatment Outcome

KW - Cohort Studies

KW - Survival Rate

KW - Follow-Up Studies

KW - Chemotherapy, Adjuvant

KW - Remission Induction

KW - Neoplasm Invasiveness

KW - Antibodies, Monoclonal, Humanized

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Cyclophosphamide/administration & dosage

KW - Antibodies, Monoclonal/administration & dosage

KW - Breast Neoplasms/drug therapy/mortality/pathology

KW - Carcinoma, Ductal, Breast/drug therapy/mortality/pathology

KW - Carcinoma, Lobular/drug therapy/mortality/pathology

KW - Epirubicin/administration & dosage

KW - Neoadjuvant Therapy

KW - Paclitaxel/administration & dosage

KW - Receptor, erbB-2/metabolism